Bioavailability of phytochemicals and its enhancement by drug delivery systems

Cancer Letters

Volumn 334, Issue 1, 2013, Pages 133-141

  Aqil, Farrukh ^a   Munagala, Radha ^a   Jeyabalan, Jeyaprakash ^a   Vadhanam, Manicka V ^a  

^a UNIVERSITY OF LOUISVILLE   (United States)

Author keywords

Bioavailability; Chemoprevention; Drug delivery; Nanochemoprevention; Nanoparticles; Polymeric implant

Indexed keywords

CURCUMIN; CYCLODEXTRIN; DOXORUBICIN; LIPOSOME; NANOPARTICLE; NIOSOME; WITHAFERIN A; ANTINEOPLASTIC AGENT; MICELLE; PLANT MEDICINAL PRODUCT;

ANTINEOPLASTIC ACTIVITY; BIOCOMPATIBILITY; CANCER CELL; CLINICAL EFFECTIVENESS; DRUG BIOAVAILABILITY; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG METABOLISM; DRUG POTENCY; DRUG RELEASE; DRUG SAFETY; DRUG SOLUBILITY; DRUG STABILITY; HUMAN; HYDROPHILICITY; HYDROPHOBICITY; IMPLANT DELIVERY DEVICE; LIMIT OF DETECTION; LUNG CANCER; NANOENCAPSULATION; NONHUMAN; OXIDATIVE STRESS; PARTICLE SIZE; PHYTOCHEMISTRY; POLYMERIZATION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SHORT SURVEY; SURFACE PROPERTY; BIOAVAILABILITY; MICELLE; PROCEDURES;

ANTICARCINOGENIC AGENTS; BIOLOGICAL AVAILABILITY; CYCLODEXTRINS; DRUG DELIVERY SYSTEMS; HUMANS; LIPOSOMES; MICELLES; NANOPARTICLES; PHYTOCHEMICALS;

EID: 84885028124     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.02.032     Document Type: Review

References (152)

1. Pezzuto J.M. Plant-derived anticancer agents. Biochem. Pharmacol. 1997, 53:121-133.
2. Riboli E., Norat T. Epidemiologic evidence of the protective effect of fruit and vegetables on cancer risk. Am. J. Clin. Nutr. 2003, 78:559S-569S.
3. Key T.J., Schatzkin A., Willett W.C., Allen N.E., Spencer E.A., Travis R.C. Diet, nutrition and the prevention of cancer. Public Health Nutr. 2004, 7:187-200.
4. Hung H.C., Joshipura K.J., Jiang R., Hu F.B., Hunter D., Smith-Warner S.A., Colditz G.A., Rosner B., Spiegelman D., Willett W.C. Fruit and vegetable intake and risk of major chronic disease. J. Natl. Cancer Inst. 2004, 96:1577-1584.
5. Lippman S.M., Klein E.A., Goodman P.J., Lucia M.S., Thompson I.M., Ford L.G., Parnes H.L., Minasian L.M., Gaziano J.M., Hartline J.A., Parsons J.K., Bearden J.D., Crawford E.D., Goodman G.E., Claudio J., Winquist E., Cook E.D., Karp D.D., Walther P., Lieber M.M., Kristal A.R., Darke A.K., Arnold K.B., Ganz P.A., Santella R.M., Albanes D., Taylor P.R., Probstfield J.L., Jagpal T.J., Crowley J.J., Meyskens F.L., Baker L.H., Coltman C.A. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Jama 2009, 301:39-51.
6. Klein E.A., Thompson I.M., Tangen C.M., Crowley J.J., Lucia M.S., Goodman P.J., Minasian L.M., Ford L.G., Parnes H.L., Gaziano J.M., Karp D.D., Lieber M.M., Walther P.J., Klotz L., Parsons J.K., Chin J.L., Darke A.K., Lippman S.M., Goodman G.E., Meyskens F.L., Baker L.H. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Jama 2011, 306:1549-1556.
7. Marshall J.R., Tangen C.M., Sakr W.A., Wood D.P., Berry D.L., Klein E.A., Lippman S.M., Parnes H.L., Alberts D.S., Jarrard D.F., Lee W.R., Gaziano J.M., Crawford E.D., Ely B., Ray M., Davis W., Minasian L.M., Thompson I.M. Phase III trial of selenium to prevent prostate cancer in men with high-grade prostatic intraepithelial neoplasia: SWOG S9917. Cancer Prev. Res. (Phila) 2011, 4:1761-1769.
8. Hercberg S., Galan P., Preziosi P., Bertrais S., Mennen L., Malvy D., Roussel A.M., Favier A., Briancon S. The SU.VI.MAX Study: a randomized, placebo-controlled trial of the health effects of antioxidant vitamins and minerals. Arch. Intern. Med. 2004, 164:2335-2342.
9. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. New Engl. J. Med. 1994, 330:1029-1035.
10. Meyskens F.L., Szabo E. Diet and cancer: the disconnect between epidemiology and randomized clinical trials. Cancer Epidemiol. Biomarkers Prev. 2005, 14:1366-1369.
11. Martinez M.E., Jacobs E.T., Baron J.A., Marshall J.R., Byers T. Dietary supplements and cancer prevention: balancing potential benefits against proven harms. J. Natl. Cancer Inst. 2012, 104:732-739.
12. Willett W.C. Diet and cancer: an evolving picture. Jama 2005, 293:233-234.
13. Blackburn E.H. Cancer interception. Cancer Prev. Res. (Phila) 2011, 4:787-792.
14. Gullett N.P., Ruhul Amin A.R., Bayraktar S., Pezzuto J.M., Shin D.M., Khuri F.R., Aggarwal B.B., Surh Y.J., Kucuk O. Cancer prevention with natural compounds. Semin. Oncol. 2010, 37:258-281.
15. Naithani R., Huma L.C., Moriarty R.M., McCormick D.L., Mehta R.G. Comprehensive review of cancer chemopreventive agents evaluated in experimental carcinogenesis models and clinical trials. Curr. Med. Chem. 2008, 15:1044-1071.
16. Cheng A.L., Hsu C.H., Lin J.K., Hsu M.M., Ho Y.F., Shen T.S., Ko J.Y., Lin J.T., Lin B.R., Ming-Shiang W., Yu H.S., Jee S.H., Chen G.S., Chen T.M., Chen C.A., Lai M.K., Pu Y.S., Pan M.H., Wang Y.J., Tsai C.C., Hsieh C.Y. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res. 2001, 21:2895-2900.
17. Lipinski C.A., Lombardo F., Dominy B.W., Feeney P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 2001, 46:3-26.
18. Gao S., Hu M. Bioavailability challenges associated with development of anti-cancer phenolics. Mini. Rev. Med. Chem. 2010, 10:550-567.
19. Murugan V., Mukherjee K., Maiti K., Mukherjee P.K. Enhanced oral bioavailability and antioxidant profile of ellagic acid by phospholipids. J. Agric. Food Chem. 2009, 57:4559-4565.
20. Pettit G.R., Anderson C.R., Gapud E.J., Jung M.K., Knight J.C., Hamel E., Pettit R.K. Antineoplastic agents, 515. Synthesis of human cancer cell growth inhibitors derived from 3,4-methylenedioxy-5,4'-dimethoxy-3'-amino-Z-stilbene. J. Nat. Prod. 2005, 68:1191-1197.
21. Yang C.S., Sang S., Lambert J.D., Lee M.J. Bioavailability issues in studying the health effects of plant polyphenolic compounds. Mol. Nutr. Food Res. 2008, 52(Suppl. 1):S139-S151.
22. Zolk O., Fromm M.F. Transporter-mediated drug uptake and efflux: important determinants of adverse drug reactions. Clin. Pharmacol. Ther. 2011, 89:798-805.
23. Kusuhara H., Sugiyama Y. Role of transporters in the tissue-selective distribution and elimination of drugs: transporters in the liver, small intestine, brain and kidney. J. Control. Release 2002, 78:43-54.
24. Li Y., Paxton J.W. Oral bioavailability and disposition of phytochemicals. Phytochemicals - Bioactivities and Impact on Health 2011, 117-138. InTech, Rijeka, Croatia. I. Rasooli (Ed.).
25. Manach C., Scalbert A., Morand C., Remesy C., Jimenez L. Polyphenols: food sources and bioavailability. Am. J. Clin. Nutr. 2004, 79:727-747.
26. Wu B., Kulkarni K., Basu S., Zhang S., Hu M. First-pass metabolism via UDP-glucuronosyltransferase: a barrier to oral bioavailability of phenolics. J. Pharm. Sci. 2011, 100:3655-3681.
27. Emoto C., Murayama N., Rostami-Hodjegan A., Yamazaki H. Methodologies for investigating drug metabolism at the early drug discovery stage: prediction of hepatic drug clearance and P450 contribution. Curr. Drug Metab. 2010, 11:678-685.
28. Atal C.K., Zutshi U., Rao P.G. Scientific evidence on the role of Ayurvedic herbals on bioavailability of drugs. J. Ethnopharmacol. 1981, 4:229-232.
29. Atal C.K., Dubey R.K., Singh J. Biochemical basis of enhanced drug bioavailability by piperine - evidence that piperine is a potent inhibitor of drug-metabolism. J. Pharmacol. Exp. Ther. 1985, 232:258-262.
30. Lambert J.D., Hong J., Kim D.H., Mishin V.M., Yang C.S. Piperine enhances the bioavailability of the tea polyphenol(-)-epigallocatechin-3-gallate in mice. J. Nutr. 2004, 134:1948-1952.
31. Srinivasan K. Black pepper and its pungent principle-piperine: a review of diverse physiological effects. Crit. Rev. Food Sci. Nutr. 2007, 47:735-748.
32. Khajuria A., Thusu N., Zutshi U. Piperine modulates permeability characteristics of intestine by inducing alterations in membrane dynamics: influence on brush border membrane fluidity, ultrastructure and enzyme kinetics. Phytomedicine 2002, 9:224-231.
33. Ravindranath V., Chandrasekhara N. Metabolism of curcumin-studies with [3H] curcumin. Toxicology 1981, 22:337-344.
34. Pan M.H., Huang T.M., Lin J.K. Biotransformation of curcumin through reduction and glucuronidation in mice. Drug Metab. Dispos. 1999, 27:486-494.
35. Shoba G., Joy D., Joseph T., Majeed M., Rajendran R., Srinivas P.S. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med. 1998, 64:353-356.
36. Shaikh J., Ankola D.D., Beniwal V., Singh D., Kumar M.N. Nanoparticle encapsulation improves oral bioavailability of curcumin by at least 9-fold when compared to curcumin administered with piperine as absorption enhancer. Eur. J. Pharm. Sci. 2009, 37:223-230.
37. Ndiaye M., Kumar R., Ahmad N. Resveratrol in cancer management: where are we and where we go from here?. Ann. Ny. Acad. Sci. 2011, 1215:144-149.
38. Shankar S., Singh G., Srivastava R.K. Chemoprevention by resveratrol: molecular mechanisms and therapeutic potential. Frontiers Biosci.: A J. Virt. Libr. 2007, 12:4839-4854.
39. de Santi C., Pietrabissa A., Mosca F., Pacifici G.M. Glucuronidation of resveratrol, a natural product present in grape and wine, in the human liver. Xenobiotica 2000, 30:1047-1054.
40. De Santi C., Pietrabissa A., Spisni R., Mosca F., Pacifici G.M. Sulphation of resveratrol, a natural compound present in wine, and its inhibition by natural flavonoids. Xenobiotica 2000, 30:857-866.
41. la Porte C., Voduc N., Zhang G., Seguin I., Tardiff D., Singhal N., Cameron D.W. Steady-state pharmacokinetics and tolerability of trans-resveratrol 20000mg twice daily with food, quercetin and alcohol (ethanol) in healthy human subjects. Clin. Pharmacokinet. 2010, 49:449-454.
42. Bansal S.S., Goel M., Aqil F., Vadhanam M.V., Gupta R.C. Advanced drug delivery systems of curcumin for cancer chemoprevention. Cancer Prevent. Res. 2011, 4:1158-1171.
43. Mishra B., Patel B.B., Tiwari S. Colloidal nanocarriers: a review on formulation technology, types and applications toward targeted drug delivery. Nanomed.-Nanotechnol. 2010, 6:9-24.
44. Oerlemans C., Bult W., Bos M., Storm G., Nijsen J.F.W., Hennink W.E. Polymeric micelles in anticancer therapy: targeting, imaging and triggered release. Pharm. Res. 2010, 27:2569-2589.
45. Khan J.A., Kainthan R.K., Ganguli M., Kizhakkedathu J.N., Singh Y., Maiti S. Water soluble nanoparticles from PEG-based cationic hyperbranched polymer and RNA that protect RNA from enzymatic degradation. Biomacromolecules 2006, 7:1386-1388.
46. Schluep T., Hwang J., Hildebrandt I.J., Czernin J., Choi C.H.J., Alabi C.A., Mack B.C., Davis M.E. Pharmacokinetics and tumor dynamics of the nanoparticle IT-101 from PET imaging and tumor histological measurements. Proc. Natl. Acad. Sci. USA 2009, 106:11394-11399.
47. Italia J.L., Bhatt D.K., Bhardwaj V., Tikoo K., Kumar M.N.V.R. PLGA nanoparticles for oral delivery of cyclosporine: Nephrotoxicity and pharmacokinetic studies in comparison to Sandimmune Neoral (R). J. Control. Release 2007, 119:197-206.
48. Grabovac V., Bernkop-Schnurch A. Development and in vitro evaluation of surface modified poly(lactide-co-glycolide) nanoparticles with chitosan-4-thiobutylamidine. Drug. Dev. Ind. Pharm. 2007, 33:767-774.
49. Davis S.S. Biomedical applications of nanotechnology - implications for drug targeting and gene therapy. Trends Biotechnol. 1997, 15:217-224.
50. Brannon-Peppas L., Blanchette J.O. Nanoparticle and targeted systems for cancer therapy. Adv. Drug. Deliver. Rev. 2004, 56:1649-1659.
51. Kataoka K., Harada A., Nagasaki Y. Block copolymer micelles for drug delivery: design, characterization and biological significance. Adv. Drug. Deliver. Rev. 2001, 47:113-131.
52. Yokoyama M., Okano T., Sakurai Y., Ekimoto H., Shibazaki C., Kataoka K. Toxicity and antitumor-activity against solid tumors of micelle-forming polymeric anticancer drug and its extremely long circulation in blood. Cancer Res. 1991, 51:3229-3236.
53. Pinto Reis C., Neufeld R.J., Ribeiro A.J., Veiga F. Nanoencapsulation I. Methods for preparation of drug-loaded polymeric nanoparticles. Nanomed.: Nanotechnol., Biol., Med. 2006, 2:8-21.
54. Panyam J., Labhasetwar V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv. Drug Deliv. Rev. 2003, 55:329-347.
55. Alexis F., Basto P., Levy-Nissenbaum E., Radovic-Moreno A.F., Zhang L., Pridgen E., Wang A.Z., Marein S.L., Westerhof K., Molnar L.K., Farokhzad O.C. HER-2-targeted nanoparticle-affibody bioconjugates for cancer therapy. ChemMedChem 2008, 3:1839-1843.
56. Sulfikkarali N., Krishnakumar N., Manoharan S., Nirmal R.M. Chemopreventive efficacy of naringenin-loaded nanoparticles in 7,12-dimethylbenz(a)anthracene Induced Experimental Oral Carcinogenesis. Pathol. Oncol. Res. 2012.
57. Bisht S., Feldmann G., Soni S., Ravi R., Karikar C., Maitra A. Polymeric nanoparticle-encapsulated curcumin (" nanocurcumin"): a novel strategy for human cancer therapy. J. Nanobiotechnol. 2007, 5:3.
58. Siddiqui I.A., Adhami V.M., Bharali D.J., Hafeez B.B., Asim M., Khwaja S.I., Ahmad N., Cui H.D., Mousa S.A., Mukhtar H. Introducing nanochemoprevention as a novel approach for cancer control: proof of principle with green tea polyphenol epigallocatechin-3-gallate. Cancer Res. 2009, 69:1712-1716.
59. Hu B., Ting Y.W., Yang X.Q., Tang W.P., Zeng X.X., Huang Q.R. Nanochemoprevention by encapsulation of (-)-epigallocatechin-3-gallate with bioactive peptides/chitosan nanoparticles for enhancement of its bioavailability. Chem. Commun. 2012, 48:2421-2423.
60. des Rieux A., Fievez V., Garinot M., Schneider Y.J., Preat V. Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach. J. Control. Release 2006, 116:1-27.
61. Bae Y., Fukushima S., Harada A., Kataoka K. Design of environment-sensitive supramolecular assemblies for intracellular drug delivery: polymeric micelles that are responsive to intracellular pH change. Angew. Chem. Int. Ed. 2003, 42:4640-4643.
62. Xue Y.N., Huang Z.Z., Zhang J.T., Liu M., Zhang M., Huang S.W., Zhuo R.X. Synthesis and self-assembly of amphiphilic poly(acrylic acid-b-DL-lactide) to form micelles for pH-responsive drug delivery. Polymer 2009, 50:3706-3713.
63. Zhao Y. Photocontrollable block copolymer micelles: what can we control?. J. Mater. Chem. 2009, 19:4887-4895.
64. Gil E.S., Hudson S.M. Stimuli-reponsive polymers and their bioconjugates. Prog. Polym. Sci. 2004, 29:1173-1222.
65. Colson Y.L., Grinstaff M.W. Biologically responsive polymeric nanoparticles for drug delivery. Adv. Mater. 2012, 24:3878-3886.
66. Shenoy D., Little S., Langer R., Amiji M. Poly(ethylene oxide)-modified poly(beta-amino ester) nanoparticles as a pH-sensitive system for tumor-targeted delivery of hydrophobic drugs: Part 2. In vivo distribution and tumor localization studies. Pharm. Res. 2005, 22:2107-2114.
67. Devalapally H., Shenoy D., Little S., Langer R., Amiji M. Poly(ethylene oxide)-modified poly(beta-amino ester) nanoparticles as a pH-sensitive system for tumor-targeted delivery of hydrophobic drugs: Part 3. Therapeutic efficacy and safety studies in ovarian cancer xenograft model. Cancer Chemoth. Pharm. 2007, 59:477-484.
68. Maurer-Jones M.A., Bantz K.C., Love S.A., Marquis B.J., Haynes C.L. Toxicity of therapeutic nanoparticles. Nanomedicine (Lond) 2009, 4:219-241.
69. Nel A., Xia T., Madler L., Li N. Toxic potential of materials at the nanolevel. Science 2006, 311:622-627.
70. Sharifi S., Behzadi S., Laurent S., Forrest M.L., Stroeve P., Mahmoudi M. Toxicity of nanomaterials. Chem. Soc. Rev. 2012, 41:2323-2343.
71. Service R.F. Nanotoxicology: nanotechnology grows up. Science 2004, 304:1732-1734.
72. Colvin V.L. The potential environmental impact of engineered nanomaterials (vol 21, pg 1166). Nat. Biotechnol. 2003, 22(2004):760.
73. Chervenkov T., Ivanova D., Galunska B., Gerova D., Yankova T. Toxicity of polymeric nanoparticles with respect to their application as drug carriers. Nanotechnology - Toxicological Issues and Environmental Safety 2007, 111-118. Springer, Netherlands. P.P. Simeonova, N. Opopol, M.I. Luster (Eds.).
74. Meng H., Chen Z., Xing G.M., Yuan H., Chen C.Y., Zhao F., Zhang C.C., Zhao Y.L. Ultrahigh reactivity provokes nanotoxicity: explanation of oral toxicity of nano-copper particles. Toxicol. Lett. 2007, 175:102-110.
75. Cho M., Cho W.S., Choi M., Kim S.J., Han B.S., Kim S.H., Kim H.O., Sheen Y.Y., Jeong J. The impact of size on tissue distribution and elimination by single intravenous injection of silica nanoparticles. Toxicol. Lett. 2009, 189:177-183.
76. Chen H.W., Su S.F., Chien C.T., Lin W.H., Yu S.L., Chou C.C., Chen J.J.W., Yang P.C. Titanium dioxide nanoparticles induce emphysema-like lung injury in mice. Faseb. J. 2006, 20:2393.
77. Chen Y.S., Hung Y.C., Liau I., Huang G.S. Assessment of the in vivo toxicity of gold nanoparticles. Nanoscale Res. Lett. 2009, 4:858-864.
78. Park E.J., Bae E., Yi J., Kim Y., Choi K., Lee S.H., Yoon J., Lee B.C., Park K. Repeated-dose toxicity and inflammatory responses in mice by oral administration of silver nanoparticles. Environ. Toxicol. Pharmacol. 2010, 30:162-168.
79. Zhang Y., Chen W., Zhang J., Liu J., Chen G., Pope C. In vitro and in vivo toxicity of CdTe nanoparticles. J. Nanosci. Nanotechnol. 2007, 7:497-503.
80. Semete B., Booysen L., Lemmer Y., Kalombo L., Katata L., Verschoor J., Swai H.S. In vivo evaluation of the biodistribution and safety of PLGA nanoparticles as drug delivery systems. Nanomed.-Nanotechnol. Biol. Med. 2010, 6:662-671.
81. Gao X.J., Zhang X.G., Zhang X.J., Cheng C., Wang Z., Li C.X. Encapsulation of BSA in polylactic acid-hyperbranched polyglycerol conjugate nanoparticles: preparation, characterization, and release kinetics. Polym. Bull. 2010, 65:787-805.
82. Gregoriadis G. Immunological adjuvants: a role for liposomes. Immunol. Today 1990, 11:89-97.
83. Alving C.R. Liposomes as carriers of antigens and adjuvants. J. Immunol. Methods 1991, 140:1-13.
84. Sharma A., Sharma U.S. Liposomes in drug delivery: progress and limitations. Int. J. Pharm. 1997, 154:123-140.
85. Vanrooijen N., Vannieuwmegen R. Liposomes in immunology - multilamellar phosphatidylcholine liposomes as a simple, biodegradable and harmless adjuvant without any immunogenic activity of its own. Immunol. Commun. 1980, 9:243-256.
86. Campbell P.I. Toxicity of some charged lipids used in liposome preparations. Cytobios 1983, 37:21-26.
87. Harrington K.J., Syrigos K.N., Vile R.G. Liposomally targeted cytotoxic drugs for the treatment of cancer. J. Pharm. Pharmacol. 2002, 54:1573-1600.
88. Zhou F., Neutra M.R. Antigen delivery to mucosa-associated lymphoid tissues using liposomes as a carrier. Biosci. Rep. 2002, 22:355-369.
89. Matteucci M.L., Thrall D.E. The role of liposomes in drug delivery and diagnostic imaging: a review. Vet. Radiol. Ultrasoun. 2000, 41:100-107.
90. Mady M.M., Ghannam M.M., Khalil W.A., Repp R., Markus M., Rascher W., Muller R., Fahr A. Efficient gene delivery with serum into human cancer cells using targeted anionic liposomes. J. Drug Target. 2004, 12:11-18.
91. Chaize B., Colletier J.P., Winterhalter M., Fournier D. Encapsulation of enzymes in liposomes: high encapsulation efficiency and control of substrate permeability. Artif. Cell Blood. Sub. 2004, 32:67-75.
92. Koo O.M., Rubinstein I., Onyuksel H. Role of nanotechnology in targeted drug delivery and imaging: a concise review. Nanomed.: Nanotechnol., Biol., Med. 2005, 1:193-212.
93. Basu M.K., Lala S. Macrophage specific drug delivery in experimental leishmaniasis. Curr. Mol. Med. 2004, 4:681-689.
94. Agrawal A.K., Gupta C.M. Tuftsin-bearing liposomes in treatment of macrophage-based infections. Adv. Drug Deliver. Rev. 2000, 41:135-146.
95. Jain R.K. Delivery of molecular and cellular medicine to solid tumors. J. Control. Release 1998, 53:49-67.
96. Symon Z., Peyser A., Tzemach D., Lyass O., Sucher E., Shezen E., Gabizon A. Selective delivery of doxorubicin to patients with breast carcinoma metastases by stealth liposomes. Cancer 1999, 86:72-78.
97. Gabizon A., Martin F. Polyethylene glycol coated (pegylated) liposomal doxorubicin - rationale for use in solid tumours. Drugs 1997, 54:15-21.
98. Gabizon A.A. Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy. Cancer Invest. 2001, 19:424-436.
99. Kwon G.S. Block copolymer micelles as drug delivery systems. Adv. Drug. Deliver. Rev. 2002, 54:167.
100. Kwon G.S., Okano T. Polymeric micelles as new drug carriers. Adv. Drug. Deliver. Rev. 1996, 21:107-116.
101. Teng Y., Morrison M.E., Munk P., Webber S.E., Prochazka K. Release kinetics studies of aromatic molecules into water from block polymer micelles. Macromolecules 1998, 31:3578-3587.
102. Rapoport N. Physical stimuli-responsive polymeric micelles for anti-cancer drug delivery. Prog. Polym. Sci. 2007, 32:962-990.
103. Zia Q., Farzuddin M., Ansari M.A., Alam M., Ali A., Ahmad A., Owais M. Novel drug delivery systems for antifungal compounds. Combating Fungal Infections 2010, 485-528. Springer-Verlag, Berlin, Heidelberg. I. Ahmad, M. Owais, M. Shahid, F. Aqil (Eds.).
104. Mikhail A.S., Allen C. Block copolymer micelles for delivery of cancer therapy: transport at the whole body, tissue and cellular levels. J. Control. Release 2009, 138:214-223.
105. Maeda H., Wu J., Sawa T., Matsumura Y., Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J. Control. Release 2000, 65:271-284.
106. Gong J., Chen M., Zheng Y., Wang S., Wang Y. Polymeric micelles drug delivery system in oncology. J. Control. Release 2012, 159:312-323.
107. Kloover J.S., den Bakker M.A., Gelderblom H., van Meerbeeck J.P. Fatal outcome of a hypersensitivity reaction to paclitaxel: a critical review of premedication regimens. Brit. J. Cancer 2004, 90:304-305.
108. Rijcken C.J.F., Soga O., Hennink W.E., van Nostrum C.F. Triggered destabilisation of polymeric micelles and vesicles by changing polymers polarity: an attractive tool for drug delivery. J. Control. Release 2007, 120:131-148.
109. Xiao Y.L., Hong H., Javadi A., Engle J.W., Xu W.J., Yang Y.A., Zhang Y., Barnhart T.E., Cai W.B., Gong S.Q. Multifunctional unimolecular micelles for cancer-targeted drug delivery and positron emission tomography imaging. Biomaterials 2012, 33:3071-3082.
110. Chen Y.C., Lo C.L., Lin Y.F., Hsiue G.H. Rapamycin encapsulated in dual-responsive micelles for cancer therapy. Biomaterials 2013, 34:1115-1127.
111. Matsumura Y., Kataoka K. Preclinical and clinical studies of anticancer agent-incorporating polymer micelles. Cancer Sci. 2009, 100:572-579.
112. Hamaguchi T., Matsumura Y., Suzuki M., Shimizu K., Goda R., Nakamura I., Nakatomi I., Yokoyama M., Kataoka K., Kakizoe T. NK105, a paclitaxel-incorporating micellar nanoparticle formulation, can extend in vivo antitumour activity and reduce the neurotoxicity of paclitaxel. Brit. J. Cancer 2005, 92:1240-1246.
113. Malhotra M., Jain N.K. Niosomes as drug carriers. Indian Drugs 1994, 31:81-86.
114. Uchegbu I.F., Vyas S.P. Non-ionic surfactant based vesicles (niosomes) in drug delivery (vol. 172, pp. 33. Int. J. Pharm. 1998, 176(1998):139.
115. Jain S., Singh P., Mishra V., Vyas S.P. Mannosylated niosomes as adjuvant-carrier system for oral genetic immunization against Hepatitis B. Immunol. Lett. 2005, 101:41-49.
116. Balasubramaniam A., Kumar V.A., Pillai K.S. Formulation and in vivo evaluation of niosome-encapsulated daunorubicin hydrochloride. Drug Dev. Ind. Pharm. 2002, 28:1181-1193.
117. Gude R.P., Jadhav M.G., Rao S.G., Jagtap A.G. Effects of niosomal cisplatin and combination of the same with theophylline and with activated macrophages in murine B16F10 melanoma model. Cancer Biother. Radiopharm. 2002, 17:183-192.
118. Shahiwala A., Misra A. Studies in topical application of niosomally entrapped Nimesulide. Journal of Pharmacy and Pharmaceutical Sciences: A Publication of the Canadian Society for Pharmaceutical Sciences, Societe Canadienne des Sciences Pharmaceutiques 2002, 5:220-225.
119. Choi M.J., Maibach H.I. Liposomes and niosomes as topical drug delivery systems. Skin. Pharmacol. Physi. 2005, 18:209-219.
120. Barry B.W. Novel mechanisms and devices to enable successful transdermal drug delivery. Eur. J. Pharm. Sci. 2001, 14:101-114.
121. Challa R., Ahuja A., Ali J., Khar R.K. Cyclodextrins in drug delivery: an updated review. Aaps. Pharmscitech. 2005, 6.
122. Thompson D.O. Cyclodextrins - enabling excipients: their present and future use in pharmaceuticals. Crit. Rev. Ther. Drug 1997, 14:1-104.
123. Stella V.J., Rajewski R.A. Cyclodextrins: their future in drug formulation and delivery. Pharm. Res. 1997, 14:556-567.
124. Loftsson T., Stefansson E. Effect of cyclodextrins on topical drug delivery to the eye. Drug Dev. Ind. Pharm. 1997, 23:473-481.
125. Irie T., Wakamatsu K., Arima H., Aritomi H., Uekama K. Enhancing effects of cyclodextrins on nasal absorption of insulin in rats. Int. J. Pharm. 1992, 84:129-139.
126. Harris D., Robinson J.R. Drug delivery via the mucous membranes of the oral cavity. J. Pharm. Sci. 1992, 81:1-10.
127. Uekama K., Otagiri M. Cyclodextrins in drug carrier systems. Crit. Rev. Ther. Drug Carrier Syst. 1987, 3:1-40.
128. Stevens D.A. Itraconazole in cyclodextrin solution. Pharmacotherapy 1999, 19:603-611.
129. Haller D.G., Glick J.H. Progestational agents in advanced breast cancer: an overview. Semin. Oncol. 1986, 13:2-8.
130. Stoddard A., McNicholas C., Peipert J.F. Efficacy and safety of long-acting reversible contraception. Drugs 2011, 71:969-980.
131. Schlegel P.N. Efficacy and safety of histrelin subdermal implant in patients with advanced prostate cancer. J. Urol. 2006, 175:1353-1358.
132. Kelleher S., Howe C., Conway A.J., Handelsman D.J. Testosterone release rate and duration of action of testosterone pellet implants. Clin. Endocrinol. (Oxf.) 2004, 60:420-428.
133. Saltzman W.M., Fung L.K. Polymeric implants for cancer chemotherapy. Adv. Drug Deliv. Rev. 1997, 26:209-230.
134. Darney P.D. Hormonal implants: contraception for a new century. Am. J. Obstet. Gynecol. 1994, 170:1536-1543.
135. Vadhanam M.V., Ravoori S., Aqil F., Gupta R.C. Chemoprevention of mammary carcinogenesis by sustained systemic delivery of ellagic acid. Eur. J. Cancer Prev. 2011, 20:484-491.
136. Gopferich A., Tessmar J. Polyanhydride degradation and erosion. Adv. Drug Deliv. Rev. 2002, 54:911-931.
137. Wolinsky J.B., Colson Y.L., Grinstaff M.W. Local drug delivery strategies for cancer treatment: gels, nanoparticles, polymeric films, rods, and wafers. J. Control. Release 2012, 159:14-26.
138. Exner A.A., Saidel G.M. Drug-eluting polymer implants in cancer therapy. Expert. Opin. Drug Deliv. 2008, 5:775-788.
139. Sawyer A.J., Piepmeier J.M., Saltzman W.M. New methods for direct delivery of chemotherapy for treating brain tumors. Yale J. Biol. Med. 2006, 79:141-152.
140. Zubris K.A., Colson Y.L., Grinstaff M.W. Hydrogels as intracellular depots for drug delivery. Mol. Pharm. 2012, 9:196-200.
141. Gupta R.C., Bansal S.S., Aqil F., Jeyabalan J., Cao P., Kausar H., Russell G.K., Munagala R., Ravoori S., Vadhanam M.V. Controlled-release systemic delivery - a new concept in cancer chemoprevention. Carcinogenesis 2012, 33:1608-1615.
142. Bansal S.S., Vadhanam M.V., Gupta R.C. Development and in vitro-in vivo evaluation of polymeric implants for continuous systemic delivery of curcumin. Pharm. Res. 2011, 28:1121-1130.
143. Bansal S.S., Kausar H., Aqil F., Jeyabalan J., Vadhanam M.V., Gupta R.C., Ravoori S. Curcumin implants for continous systemic delivery: safety and biocompatibility. Drug Deliv. Transl. Res. 2011, 1:332-341.
144. Bansal S.S., Kausar H., Vadhanam M.V., Ravoori S., Gupta R.C. Controlled systemic delivery by polymeric implants enhances tissue and plasma curcumin levels compared with oral administration. Eur. J. Pharm. Biopharm. 2012, 80:571-577.
145. Cao P., Vadhanam M.V., Spencer W.A., Cai J., Gupta R.C. Sustained systemic delivery of green tea polyphenols by polymeric implants significantly diminishes benzo[a]pyrene-induced DNA adducts. Chem. Res. Toxicol. 2011, 24:877-886.
146. Aqil F., Vadhanam M.V., Gupta R.C. Enhanced activity of punicalagin delivered via polymeric implants against benzo[a]pyrene-induced DNA adducts. Mutat. Res. 2012, 743:59-66.
147. Aqil F., Jeyabalan J., Kausar H., Bansal S.S., Sharma R.J., Singh I.P., Vadhanam M.V., Gupta R.C. Multi-layer polymeric implants for sustained release of chemopreventives. Cancer Lett. 2012, 326:33-40.
148. Jeyabalan J., Vadhanam M.V., Ravoori S., Gupta R.C. Sustained overexpression of CYP1A1 and 1B1 and steady accumulation of DNA adducts by low-dose, continuous exposure to benzo[a]pyrene by polymeric implants. Chem. Res. Toxicol. 2011, 24:1937-1943.
149. Desai K.G., Olsen K.F., Mallery S.R., Stoner G.D., Schwendeman S.P. Formulation and in vitro-in vivo evaluation of black raspberry extract-loaded PLGA/PLA injectable millicylindrical implants for sustained delivery of chemopreventive anthocyanins. Pharm. Res. 2010, 27:628-643.
150. Desai K.G., Mallery S.R., Schwendeman S.P. Formulation and characterization of injectable poly(DL-lactide-co-glycolide) implants loaded with N-acetylcysteine, a MMP inhibitor. Pharm. Res. 2008, 25:586-597.
151. Desai K.G., Mallery S.R., Schwendeman S.P. Effect of formulation parameters on 2-methoxyestradiol release from injectable cylindrical poly(DL-lactide-co-glycolide) implants. Eur. J. Pharm. Biopharm. 2008, 70:187-198.
152. Gupta R.C., Bansal S.S., Aqil F., Cao P., Jeyabalan J., Russell G.K., Ravoori S., Vadhanam M.V. A novel concept in delivering chemopreventive compounds. Proc. Am. Assoc. Cancer Res. 2009, 50:944.